Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2) : two multicentre, randomised, double-blind, active-controlled, phase 3 trials

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F24%3A10488430" target="_blank" >RIV/00064165:_____/24:10488430 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/24:10488430

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=KEDtjfisvp" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=KEDtjfisvp</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/S1474-4422(24)00328-4" target="_blank" >10.1016/S1474-4422(24)00328-4</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2) : two multicentre, randomised, double-blind, active-controlled, phase 3 trials

Popis výsledku v původním jazyce

Background Evobrutinib, a Bruton&apos;s tyrosine kinase (BTK) inhibitor, has shown preliminary efficacy in people with relapsing multiple sclerosis in a phase 2 trial. Here, we aimed to compare the safety and efficacy of evobrutinib with the active comparator teriflunomide in people with relapsing multiple sclerosis. Methods EvolutionRMS1 and evolutionRMS2 were two multicentre, randomised, double-blind, double-dummy, active- controlled, phase 3 trials conducted at 701 multiple sclerosis centres and neurology clinics in 52 countries. Adults aged 18-55 years with relapsing multiple sclerosis (Expanded Disability Status Scale [EDSS] score of 0.0-5&lt;middle dot&gt;5) were included. Participants were randomly assigned (1:1) using a central interactive web response system to receive either evobrutinib (45 mg twice per day with placebo once per day) or teriflunomide (14 mg once per day with placebo twice per day), all taken orally and in an unfasted state, with randomisation stratified by geographical region and baseline EDSS. All study staff and participants were masked to the study interventions. The primary endpoint for each study was annualised relapse rate based on adjudicated qualified relapses up to 156 weeks, assessed in the full analysis set (defined as all randomly assigned participants) with a negative binomial model. These studies are registered with ClinicalTrials.gov (NCT04338022 for evolutionRMS1 and NCT04338061 for evolutionRMS2, both are terminated). Findings The primary analysis was done using data for 2290 randomly assigned participants collected from June 12, 2020, to Oct 2, 2023. 1124 participants were included in the full analysis set in evolutionRMS1 (560 in the evobrutinib group and 564 in the teriflunomide group) and 1166 in evolutionRMS2 (583 in each group). 751 (66.8%) participants were female and 373 (33.1%) were male in evolutionRMS1, whereas 783 (67.2%) were female and 383 (32.8%) were male in evolutionRMS2. Annualised relapse rate was 0&lt;middle dot&gt;15 (95% CI 0&lt;middle dot&gt;12-0&lt;middle dot&gt;18 with evobrutinib vs 0&lt;middle dot&gt;14 [0&lt;middle dot&gt;11-0&lt;middle dot&gt;18] with teriflunomide (adjusted RR 1&lt;middle dot&gt;02 [0&lt;middle dot&gt;75-1&lt;middle dot&gt;39]; p=0&lt;middle dot&gt;55) in evolutionRMS1 and 0&lt;middle dot&gt;11 (0&lt;middle dot&gt;09-0&lt;middle dot&gt;13 vs 0&lt;middle dot&gt;11 [0&lt;middle dot&gt;09-0&lt;middle dot&gt;13]; adjusted RR 1&lt;middle dot&gt;00 [0&lt;middle dot&gt;74-1&lt;middle dot&gt;35]; p=0&lt;middle dot&gt;51) in evolutionRMS2. The pooled proportion of participants with any treatment-emergent adverse event (TEAE) was similar between treatment groups (976 [85&lt;middle dot&gt;6%] of 1140 with evobrutinib vs 999 [87&lt;middle dot&gt;2%] of 1146 with teriflunomide). The most frequently reported TEAEs were COVID-19 (223 [19&lt;middle dot&gt;6%] with evobrutinib vs 223 [19&lt;middle dot&gt;5%] with teriflunomide), alanine aminotransferase increased (173 [15.2%] vs 204 [17.8%]), aspartate aminotransferase increased (110 [9.6%] vs 131 [11.4%]), and headache (175 [15&lt;middle dot&gt;4%] vs 176 [15&lt;middle dot&gt;4%]). Serious TEAE incidence rates were higher with evobrutinib than teriflunomide (86 [7.5%] vs 64 [5.6%]). Liver enzyme elevations at least 5 x upper limit of normal were more common with evobrutinib than with teriflunomide, particularly in the first 12 weeks (55 [5&lt;middle dot&gt;0%] vs nine [&lt;1%]). Three people who received evobrutinib and one who received teriflunomide met the biochemical definition of Hy&apos;s law; all cases resolved after discontinuation of treatment. There were two deaths (one in each group), neither related to study treatment. Interpretation The efficacy of evobrutinib was not superior to that of teriflunomide. Together, efficacy and liver-related safety findings do not support the use of evobrutinib in people with relapsing multiple sclerosis.

Název v anglickém jazyce

Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2) : two multicentre, randomised, double-blind, active-controlled, phase 3 trials

Popis výsledku anglicky

Background Evobrutinib, a Bruton&apos;s tyrosine kinase (BTK) inhibitor, has shown preliminary efficacy in people with relapsing multiple sclerosis in a phase 2 trial. Here, we aimed to compare the safety and efficacy of evobrutinib with the active comparator teriflunomide in people with relapsing multiple sclerosis. Methods EvolutionRMS1 and evolutionRMS2 were two multicentre, randomised, double-blind, double-dummy, active- controlled, phase 3 trials conducted at 701 multiple sclerosis centres and neurology clinics in 52 countries. Adults aged 18-55 years with relapsing multiple sclerosis (Expanded Disability Status Scale [EDSS] score of 0.0-5&lt;middle dot&gt;5) were included. Participants were randomly assigned (1:1) using a central interactive web response system to receive either evobrutinib (45 mg twice per day with placebo once per day) or teriflunomide (14 mg once per day with placebo twice per day), all taken orally and in an unfasted state, with randomisation stratified by geographical region and baseline EDSS. All study staff and participants were masked to the study interventions. The primary endpoint for each study was annualised relapse rate based on adjudicated qualified relapses up to 156 weeks, assessed in the full analysis set (defined as all randomly assigned participants) with a negative binomial model. These studies are registered with ClinicalTrials.gov (NCT04338022 for evolutionRMS1 and NCT04338061 for evolutionRMS2, both are terminated). Findings The primary analysis was done using data for 2290 randomly assigned participants collected from June 12, 2020, to Oct 2, 2023. 1124 participants were included in the full analysis set in evolutionRMS1 (560 in the evobrutinib group and 564 in the teriflunomide group) and 1166 in evolutionRMS2 (583 in each group). 751 (66.8%) participants were female and 373 (33.1%) were male in evolutionRMS1, whereas 783 (67.2%) were female and 383 (32.8%) were male in evolutionRMS2. Annualised relapse rate was 0&lt;middle dot&gt;15 (95% CI 0&lt;middle dot&gt;12-0&lt;middle dot&gt;18 with evobrutinib vs 0&lt;middle dot&gt;14 [0&lt;middle dot&gt;11-0&lt;middle dot&gt;18] with teriflunomide (adjusted RR 1&lt;middle dot&gt;02 [0&lt;middle dot&gt;75-1&lt;middle dot&gt;39]; p=0&lt;middle dot&gt;55) in evolutionRMS1 and 0&lt;middle dot&gt;11 (0&lt;middle dot&gt;09-0&lt;middle dot&gt;13 vs 0&lt;middle dot&gt;11 [0&lt;middle dot&gt;09-0&lt;middle dot&gt;13]; adjusted RR 1&lt;middle dot&gt;00 [0&lt;middle dot&gt;74-1&lt;middle dot&gt;35]; p=0&lt;middle dot&gt;51) in evolutionRMS2. The pooled proportion of participants with any treatment-emergent adverse event (TEAE) was similar between treatment groups (976 [85&lt;middle dot&gt;6%] of 1140 with evobrutinib vs 999 [87&lt;middle dot&gt;2%] of 1146 with teriflunomide). The most frequently reported TEAEs were COVID-19 (223 [19&lt;middle dot&gt;6%] with evobrutinib vs 223 [19&lt;middle dot&gt;5%] with teriflunomide), alanine aminotransferase increased (173 [15.2%] vs 204 [17.8%]), aspartate aminotransferase increased (110 [9.6%] vs 131 [11.4%]), and headache (175 [15&lt;middle dot&gt;4%] vs 176 [15&lt;middle dot&gt;4%]). Serious TEAE incidence rates were higher with evobrutinib than teriflunomide (86 [7.5%] vs 64 [5.6%]). Liver enzyme elevations at least 5 x upper limit of normal were more common with evobrutinib than with teriflunomide, particularly in the first 12 weeks (55 [5&lt;middle dot&gt;0%] vs nine [&lt;1%]). Three people who received evobrutinib and one who received teriflunomide met the biochemical definition of Hy&apos;s law; all cases resolved after discontinuation of treatment. There were two deaths (one in each group), neither related to study treatment. Interpretation The efficacy of evobrutinib was not superior to that of teriflunomide. Together, efficacy and liver-related safety findings do not support the use of evobrutinib in people with relapsing multiple sclerosis.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

The Lancet: Neurology

ISSN

1474-4422

e-ISSN

1474-4465

Svazek periodika

23

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

14

Strana od-do

1119-1132

Kód UT WoS článku

001337790400001

EID výsledku v databázi Scopus

2-s2.0-85205515181